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Current advances in the field of drug delivery are aimed at finding adequate strategies 
for the administration of different drugs. Transmucosal delivery is the first-line option for 
the systemic delivery of many drugs, including proteins, a group of molecules with 
recognised therapeutic potential and wide range of applications (drug and genetic 
therapy, immunisation, among others). This strategy, however, demands developing 
adequate carriers, as proteins are very sensitive molecules, easily undergoing 
degradation in physiological media, mainly due to pH and enzymatic occurrences. 
Polymeric nanoparticles have taken the forefront of this carrier-design challenge, 
offering appealing properties that include a reduced size providing intimate contact with 
mucosal surfaces, which potentiates any active action of the carrier regarding 
transmucosal delivery. Nanoparticles have been generally demonstrated to improve 
protein pharmacokinetic profile, not only by providing increased stabilisation but, in 
some cases, also permitting controlled release and enhancing drug absorption [1]. 
Moreover, the high surface-to-volume ratio displayed by these carriers increases drug 
loading capacity [2]. Polysaccharides have been indicated for many years as the most 
promising materials in drug carrier development, namely regarding nanoparticles. In 
this regard, a particular emphasis is placed on chitosan. Other polysaccharides, 
however, have been paving their way, also showing great ability for protein delivery. 
Pullulan is one of those polysaccharides; the first works reporting the application of 
pullulan-based nanoparticles for drug delivery dating back to 1998, when a cholesteryl 
group-bearing pullulan was used to produce nanoparticles for the delivery of both an 
oncoprotein [3] and insulin [4].  
Pullulan is a neutral, water soluble polysaccharide produced from starch by the fungus 
Aureobasidium pullulans, by means of a process of fermentation [5]. Chemically, this 
polymer consists of α-(1,6)-linked maltotriose residues, which in turn are composed of 
three glucose molecules connected to each other by α-(1,4) glycosidic bonds [6,7]. 
Several properties have been reported for this material that make it attractive for drug 
delivery purposes, including its adhesive ability, as well as the capacity to form fibers 
and thin biodegradable films [7]. The high content of hydroxyl groups on pullulan chains 
further endows the polymer with inherent physiological activity and also provides 
chemical flexibility.  
Biodegradability is a mandatory characteristic of any material being considered for an 
application in drug delivery, and pullulan is expected to comply with it. Actually, once 
administered it will be exposed to the hydrolysis of glycoside bonds and the 
subsequent metabolism of glucose [8]. The ability to adhere to cell surfaces might also 
be advantageous within the application, improving the carriers’ residence time and, 
consequently, the potential for timely absorption of the encapsulated protein. In this 
regard, apart from the demonstrated role of pullulan on the adhesion of Aureobasidium 
pullulans to biological surfaces, such as leafs [9], cell adhesion to pullulan-based 
surfaces was reported in a number of occasions [10-12]. Pullulan-based nanoparticles 
were actually shown to adhere to the nasal epithelium in a study regarding nasal 
vaccination [13] and our group has also verified the adherence of pullulan 
nanoparticles to respiratory epithelial cells (Calu-3 and A549), although to a limited 
extent (unpublished data).  
Pullulan has been increasingly described as matrix forming material of drug and gene 
nanocarriers [5,7,13-17]. The most common characteristic of these carriers is the use 
of hydrophobic derivatives of pullulan, namely cholesteryl-pullulan, because this 
provides an amphiphilic polymer with the capacity to form nanoparticles by self-
aggregation. These nanoparticles have been demonstrated to form stable complexes 
with both hydrophobic and hydrophilic drugs, such as proteins, reinforcing their 
flexibility. In a remarkable detail, apart from the capacity to form nanocarriers with 
suitable properties for transmucosal protein delivery, it has also been shown that 
pullulan-based nanoparticles are able to preserve the structure of encapsulated 
proteins, thus ensuring their biological activity [4]. Nevertheless, although the potential 
application in protein delivery was mentioned frequently, the demonstration of results in 
the area has been scarce. The delivery of insulin, bovine serum albumin, DNA and IL-
12 was effectively proposed [4,15-18]. Our group has recently given a contribution to 
the field. Instead of using a hydrophobic derivative of pullulan, our strategy involved the 
synthesis of charged hydrophilic derivatives of the polymer that provided the possibility 
of establishing electrostatic interactions among them or with other charged materials of 
interest. From the synthesised derivatives (carboxylated, phosphorylated, aminated 
and sulphated) the latter two were used to produce polysaccharide-based 
nanoparticles, upon complexation with either chitosan or carrageenan, or even with 
each other. The carriers were produced using a mild technique of polyelectrolyte 
complexation, which only involves hydrophilic conditions and a simple mixture of 
solutions, while permitting a very rapid formation of the carriers (less than 10 minutes). 
These nanoparticles exhibited great ability for the association of proteins with distinct 
properties (insulin and BSA, molecular weight of 5.7 and 67 kDa, respectively) and 
were proposed for nasal and pulmonary transmucosal delivery. Having demonstrated a 
clear non-cytotoxic behaviour in model respiratory cell lines (Calu-3 and A549) [17], the 
nanoparticles also revealed to not induce an inflammatory response upon contact with 
the same cell lines (unpublished data). Finally, preliminary in vivo tests in rats 
demonstrated an increased therapeutic response of insulin-loaded pullulan-based 
nanoparticles administered intranasally as compared with an insulin solution of similar 
dose (unpublished data).  
The analysis of all the data available on the literature suggests the adequacy of the 
biomaterial pullulan for drug delivery strategies. Particularly, although counting on a 
reduced number of works, pullulan-based nanoparticles reveal potential regarding 
transmucosal protein delivery. The ability to associate and release biomacromolecules 
is demonstrated, good indications are available concerning biocompatibility, and 
biodegradability is also ensured. However, the real possibilities of success should be 
considered on a rational and cautious basis. Looking at chitosan nanoparticles, for 
instance, which are incomparably more explored and for a longer time, after more than 
two decades of research and really good, diverse and important demonstrations of 
effectiveness and safety, no formulation was made commercially available so far. 
Nanomedicine is still a controversial matter, mainly because of safety issues. The 
regulatory agencies demand uncountable studies and demonstrations to consider any 
approval, which is highly desirable if considering that global human health is the 
addressed subject. However, it is natural that nanomedicine, as a recent subject in the 
ambit of regulation, faces even more difficult challenges.  
As a demonstration that nanomedicine is still in its infancy regarding the regulatory 
challenges to be faced, it is interesting to consider a work from 2012 that revealed the 
significant accumulation of nanoparticles (40 – 350 nm) in the ovaries [19]. When other 
organs like the lung, liver, spleen and kidneys are usually examined by everyone to 
determine the biodistribution of nanoparticles and, thus, evaluate potential toxicity, the 
ovaries seem to have been neglected. The observation of that work raises an 
extremely important question: although in vitro cell studies give very relevant 
indications on the biocompatibility behaviour of nanocarriers, it is becoming undeniable 
that a complete characterisation of potential toxicity is only possible with early in vivo 
studies. For this reason, keeping track of the whole biological portrait and the complex 
interactions between the nanocarrier and the biological structures, which might induce 
toxicological issues, is essential when designing a nanodelivery system. 
It seems, then, that the potential of pullulan-based nanoparticles for transmucosal 
protein delivery is there, but a very long way is still ahead to cover.  
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